The latest Covid vaccines from Pfizer Inc. and Moderna Inc. are arriving at US pharmacies, spurring the annual debate over vaccination uptake. Despite evidence supporting the updated Covid shots’ timely entrance—particularly amidst a summer surge driven by new variants and waning immunity—some individuals may choose to delay receiving them.
The summer’s elevated Covid-19 metrics indicate increasing hospitalizations and deaths, disrupting the low seen in spring. Given these dynamics, public health authorities are urging those without recent infections to consider getting the updated vaccine. For many, especially vulnerable populations, these new doses could prove crucial in combating the infection’s resurgence. Conversely, individuals with recent infections might have a smaller window of immediate need, given their current immunity levels.
With these critical updates, the enduring question looms—will enough of the public heed this call in time to mitigate the virus’s impact through the winter?